Cart
sales@molnova.com
DC-BPi-03
CAS No. 2758411-46-8
DC-BPi-03( —— )
Catalog No. M36511 CAS No. 2758411-46-8
DC-BPi-03 is a potent BPTF-BRD inhibitor, exhibiting an IC50 of 698.3 nM and a Kd of 2.81 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 337 | In Stock |
|
| 5MG | 491 | In Stock |
|
| 10MG | 787 | In Stock |
|
| 25MG | 1398 | In Stock |
|
| 50MG | 1822 | In Stock |
|
| 100MG | 2403 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDC-BPi-03
-
NoteResearch use only, not for human use.
-
Brief DescriptionDC-BPi-03 is a potent BPTF-BRD inhibitor, exhibiting an IC50 of 698.3 nM and a Kd of 2.81 μM.
-
DescriptionDC-BPi-03 is a potent BPTF-BRD inhibitor with an IC50?of 698.3 nM and a Kd of 2.81 μM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorEpigenetic Reader Domain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2758411-46-8
-
Formula Weight302.35
-
Molecular FormulaC14H14N4O2S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 33.33 mg/mL (110.24 mM; Ultrasonic (<80°C)
-
SMILESO=S(=O)(C=1N=C(C=C(N1)C2=CC=C3NC=CC3=C2)NC)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Tian Lu, et al. Discovery of High-Affinity Inhibitors of the BPTF Bromodomain. J Med Chem. 2021 Aug 26;64(16):12075-12088.?
molnova catalog
related products
-
MS436
MS436 is a diazobenzene-based small-molecule inhibitor for the BRD4 bromodomains with a Ki value of 30-50 nM.
-
dBRD9 HCl
dBRD9 HCl is a PROTAC composed of the BRD9 inhibitor BI 7273 conjugated to the cereblon E3 ligase ligand pomalidomide . dBRD9 HCl is a potent and selective degrader of BRD9 (IC50 = 56.6 nM in MOLM-13 cells).
-
Curcumin
Curcumin is a natural phenolic compound with impressive antioxidant properties. Curcumin is recently proved to exert its chemopreventive effects partly through the activation of nuclear factor (erythroid-2 related) factor 2 (Nrf2).
